EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
8.0301
8.0750
Year Range
7.7400
11.4600
Daily Change
+0.37%
Monthly Change
+0.25%
6 month change
-24.81%
Year Change
-24.81%
Previous Close
8.0300
Open
8.0575
Low
8.0301
High
8.0750
Volume
159
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Drug Manufacturers—Specialty & Generic
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
13.29
Price to sales ratio
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

News